NUPR1 and neoplasm: In summary, our studies demonstrate that concurrent administration of PD‐1 mAb and pharmacological targeting of NUPR1 effectively remodel the tumor immune microenvironment, reduce macrophage‐mediated immune suppression, and promote tumor regression.